This protocol proposes to prospectively evaluate current epidemiology, pharmacologic and invasive management and clinical outcomes of patients with acute cardiovascular diseases admitted at our ICCU.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Acute cardiovascular disease admitted at our ICCU
2. Age ≥18 years;
3. Written informed consent.
Exclusion Criteria:
1\) Patients not providing consent to data collection
Primary outcome measure(s)
All-cause mortality — 30 days, 1 year Number of patients with all-cause mortality
Cardiovascular mortality — 30 days, 1 year Number of patients with cardiovascular mortality
Myocardial infarction — 30 days, 1 year Number of patients with myocardial infarction
Stent thrombosis — 30 days, 1 year Number of patients with stent thrombosis
Stroke — 30 days, 1 year Number of patients with stroke
Heart Failure — 30 days, 1 year Number of patients with heart failure
Hospitalization for heart failure — 30 days, 1 year Number of patients with hospitalization for heart failure
Bleeding — 30 days, 1 year Number of patients with bleeding
Acute kidney injury — 30 days, 1 year Number of patients with acute kidney injury
Target vessel revascularization — 30 days, 1 year Number of patients with target vessel revascularization
Target lesion revascularization — 30 days, 1 year Number of patients with target lesion revascularization
Hospital length of stay — 0 to 30 days (or more depending on diration of hospitalization) Duration of hospitalization in days
Metrics of diuretic response and decongestion — 0 to 30 days (or more depending on diration of hospitalization) Diuresis quantification, weight loss, decongestion score, etc.
Poor neurologic outcomes — 30 days, 1 year Number of patients with poor neurologic outcomes
ICCU length of stay — 0 to 30 days (or more depending on diration of hospitalization) Duration of ICCU hospitalization in days
Metrics of need for mechanical circulatory support and vasopressors/inotropes — 0 to 30 days (or more depending on diration of hospitalization) Need for MCS, MCS type and duration; need for vasopressors/inotropes, vasopressors/inotropes types and duration
Quality of life — 30 days, 1 year Quality of life assessment by various scores or questionnaires
Trial sites (1)
Facility
City
Region
Status
Department of Advanced Biomedical Sciences, University Federico II of Naples
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
